# Qian Wu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/qian-wu-2/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,734 |
| Field | CAR-T cell therapy research |
| h-index | 29 |
| i10-index | 62 |
| Last Known Institution | Fred Hutch Cancer Center |
| OpenAlex ID | https://openalex.org/A5027819567 |
| ORCID iD | 0000-0002-2292-4816 |
| Works | 241 |

## Researcher papers

- [Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians](https://scholariq.org/papers/cubic-splines-to-model-relationships-between-continuous-variables-and-outcomes-a/)
- [Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy](https://scholariq.org/papers/factors-associated-with-durable-efs-in-adult-b-cell-all-patients-achieving-mrd/)
- [Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells](https://scholariq.org/papers/late-events-after-treatment-with-cd19-targeted-chimeric-antigen-receptor/)
- [The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells](https://scholariq.org/papers/the-response-to-lymphodepletion-impacts-pfs-in-patients-with-aggressive-non/)
- [γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma](https://scholariq.org/papers/secretase-inhibition-increases-efficacy-of-bcma-specific-chimeric-antigen/)
- [A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer](https://scholariq.org/papers/a-phase-ii-trial-of-pembrolizumab-and-vorinostat-in-recurrent-metastatic-head/)
- [High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy](https://scholariq.org/papers/high-rate-of-durable-complete-remission-in-follicular-lymphoma-after-cd19-car-t/)
- [Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug–Associated Thrombosis Among Patients With Multiple Myeloma](https://scholariq.org/papers/derivation-and-validation-of-a-risk-assessment-model-for-immunomodulatory-drug/)
- [Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy](https://scholariq.org/papers/severe-cytokine-release-syndrome-is-associated-with-hematologic-toxicity/)
- [Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy](https://scholariq.org/papers/anakinra-for-refractory-cytokine-release-syndrome-or-immune-effector-cell/)
- [Comparison of Optic Canal Diameter in Children With Malignant Infantile Osteopetrosis and Normal Children and the Effects of Hematopoietic Stem Cell Transplantation on the Optic Canal Diameter](https://scholariq.org/papers/comparison-of-optic-canal-diameter-in-children-with-malignant-infantile/)

## Researcher topics

- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)

## Researcher university

- [Fred Hutch Cancer Center](https://scholariq.org/institutions/fred-hutch-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.